Windward Bio climbs 5% on $175 million IPO pricing

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Windward Bio Group (WWB.US) climbed nearly 5% during regular trading to $29.90.

The company priced its Nasdaq initial public offering to raise $175 million, excluding the over-allotment option, and simultaneously secured a $50 million private placement with Sanofi, bringing total expected proceeds to $225 million.

Windward Bio listed on the Nasdaq on Nov. 13, 2026, at an IPO price of $17 per share. The company focuses on developing ultra-long-acting antibodies for respiratory and dermatological diseases. Its lead candidate, WIN378, has shown positive interim results in asthma and is set to begin a Phase III clinical trial in September 2026.

Based on public media reports. AI-generated; not investment advice.

Source: Market Movers The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.